Clearwater International advises MBO & Co on the acquisition of a minority stake in CMN Group
Clearwater International has advised the private equity firm MBO & Co, on the acquisition of a minority stake in CMN, the leading private entity dedicated to nuclear medicine in France, to increase its capital.
Founded in 1994, the group operates four centres in the Greater Paris region and has welcomed over 35,000 patients during 2021. Driven by a constant focus on quality, innovation, and democratisation of nuclear medicine, all CMN teams share special attention on reactivity inpatient care and the affordability of treatments, more specifically all the group’s doctors follow professional state-regulated guidance.
This acknowledged expertise in its speciality has allowed CMN to be a pioneer in several aspects of its development. The group has notably obtained the very first clearance to operate a private nuclear medicine centre in South Paris, within the Hôpital Privé des Peupliers, which is expected to open in 2022.
In this highly dynamic environment, MBO & Co has provided capital for the group which will help support the next steps of its development, while the eight physician shareholders retain the majority of the capital after the operation. This capital increase will allow CMN, with the support of this new partner, to foster its growth in order to build a stronger and more independent nuclear medicine and broaden its offer across France.
The shared ambition is to build a national leader in the French nuclear medicine market while preserving the standards of excellence in care which built the success of the group.